ReviewFrontiers in cardiovascular medicine2023
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Mortality and cardiovascular risk of triglyceride-glucose and derived indices in cardiovascular-kidney-metabolic syndrome stages 0-3: a dose-response meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Trial
- Trial
- Trial
- Non-invasive vestibular nerve stimulation (VeNS) reduces visceral adipose tissue: results of a randomised controlled trial.Scientific reports · 2025Trial
- Impact of diet intervention on visceral adipose tissue and hepatic fat in patients with obesity or type 2 diabetes: a randomized trial.Scientific reports · 2024Trial
- Visceral adipose tissue and incident cardiovascular disease among individuals without diabetes: an analysis of 15 prospective cohorts from 7 countries in Latin America.Lancet regional health. Americas · 2026Article
- Predictive Performance of Seven Clinical Surrogates of Visceral Adipose Tissue for Cardiovascular Mortality: A Sub-Analysis of 102 385 Adults From the Mexico City Prospective Study.Diabetes, obesity & metabolism · 2026Article
- Growth differentiation factor-15 and body roundness index in relation to cardiometabolic risk in young adults with obesity.Endocrine · 2026Article
- Changes in Body Composition and Sexual Satisfaction Following Metabolic and Bariatric Surgery in Women with Obesity: A Prospective Study.Healthcare (Basel, Switzerland) · 2026Article
- Review
- Dietary Quality Along a Plant-Based Continuum: The Role of Added Salt, Oil, and Sugar in Chronic Disease Risk.Nutrients · 2026Review
- Article
- Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.Nature reviews. Cardiology · 2026Review
- Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5-Year Korean Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery disease.American heart journal plus : cardiology research and practice · 2026Article
- Associations of cumulative exposure and longitudinal change patterns of the triglyceride glucose-Chinese visceral adiposity index with incident cardiovascular disease in middle-aged and older adults: evidence from CHARLS.Cardiovascular diabetology · 2026Observational
- The Serpin Superfamily in Adipose Tissue Remodeling: Molecular Drivers of Immune-Metabolic Crosstalk and Insulin Sensitivity.Biology · 2026Review
- Dynamic Fuzzy-Gaussian Modeling (DynFGM): A Kurtosis-Adaptive Unsupervised Framework for Automated Adipose Tissue Segmentation in Abdominal MRI.Journal of imaging informatics in medicine · 2026Article
- Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circulation research · 2026Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a heterogeneous disease that affects almost one-third of the global population. A clear association has been established between obesity and cardiovascular disease (CVD). However, CVD risk is known to be related more to the local distribution of fat than to total body fat. Visceral adipose tissue (VAT) in particular has a high impact on CVD risk. This manuscript reviews the role of VAT in residual CV risk and the available therapeutic strategies for decreasing residual CV risk related to VAT accumulation. Among the many pathways involved in residual CV risk, obesity and particularly VAT accumulation play a major role by generating low-grade systemic inflammation, which in turn has a high prognostic impact on all-cause mortality and myocardial infarction. In recent years, many therapeutic approaches have been developed to reduce body weight. Orlistat was shown to reduce both weight and VAT but has low tolerability and many drug-drug interactions. Naltrexone-bupropion combination lowers body weight but has frequent side effects and is contraindicated in patients with uncontrolled hypertension. Liraglutide and semaglutide, glucagon-like peptide 1 (GLP-1) agonists, are the latest drugs approved for the treatment of obesity, and both have been shown to induce significant body weight loss. Liraglutide, semaglutide and other GLP-1 agonists also showed a positive effect on CV outcomes in diabetic patients. In addition, liraglutide showed to specifically reduce VAT and inflammatory biomarkers in obese patients without diabetes. GLP-1 agonists are promising compounds to limit inflammation in human visceral adipocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.